Form 4: TransDigm Group Executive Acquires Stock Options
SEC Form 4 Filing
Michael Lisman, Co-Chief Operating Officer of TransDigm Group, acquired 9,850 stock options on October 31, 2024.
Summary
- Michael Lisman, the Co-Chief Operating Officer of TransDigm Group, acquired 9,850 stock options on October 31, 2024.
- These stock options have an exercise price of $1,302.3.
- The options vest based on the achievement of annual per share operating performance targets between fiscal years 2028 and 2029.
- The options expire on October 31, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The acquisition of stock options by a top executive can be seen as a positive sign of confidence in the company's future performance.
Future Outlook
The vesting of the options is tied to the company's performance between fiscal years 2028 and 2029, indicating a long-term incentive structure.
Industry Context
This is a standard practice for executive compensation in publicly traded companies, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the aerospace and defense industry, where TransDigm operates.
- Companies like Boeing, Lockheed Martin, and Raytheon also use stock options as part of their executive compensation packages.
- The vesting period tied to performance targets is also a standard practice to incentivize long-term value creation.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of shareholders, potentially leading to increased value creation.
Key Dates
| Date | Description |
|---|---|
| 10/31/2024 | Date of the stock option acquisition. |
| 09/30/2025 | Earliest date the options can be exercised. |
| 10/31/2034 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, TransDigm Group, Michael Lisman, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.